Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

So That's What "Non-Interference" Means: CMS Defines Loaded Term in Proposed Part D Rule

This article was originally published in RPM Report

Executive Summary

The 700-page Part D proposed rule does much more than change the "protected" class list. Among many other provisions, it spells out how CMS interprets the infamous "non-interference" clause.

You may also be interested in...



When Empty Threats Work: “Price Negotiation” In White House Budget Spooks Wall Street

Investors remain hyper-sensitive to any threat to pricing flexibility for biotech products. The latest over-reaction – to a renewed call for Medicare “price negotiation” – meant missing some of the more meaningful messages coming from Washington about support for innovation.

“Non-Interference” And Part D: Prescriber Oversight Is Focus Of CMS Final Rule

CMS’ final rule on Part D is much narrower than the agency’s proposed rule—and most in industry are probably pleased by that. But it is also much more one-sided, emphasizing new tools to monitor for and correct “abusive” prescribing, without any countervailing provisions reflecting the value of appropriate medication adherence.

Class Warfare: CMS Proposes Sweeping Changes to Part D; “Protected Class” Cuts Just the Start

The Centers for Medicare & Medicaid Services is celebrating the 10th anniversary of Part D by proposing the most sweeping changes to the Medicare drug benefit since it launched. Proposed revisions to the “Protected Classes” will get the most attention, but the rest of the rule may have more profound impacts going forward.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS079685

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel